Introduction. Tuberculosis (TB) is an infectious granulomatous disease caused by the human type of bacillus Mycobacterium tuberculosis. TB infection begins when mycobacteria reach the pulmonary alveoli, where they penetrate and replicate within the endosomes of alveolar macrophages. Bacilli in the alveoli are phagocytosed by alveolar macrophages, where they multiply and spread to regional lymph glands and through the bloodstream to distant organs (miliary tuberculosis). A scar and a cavern filled with caseous necrotic material are created at the site of the affected tissue. The treatment is carried out with a combination of several drugs, most often with the joint use of rifampicin, isoniazid and pyrazinamide, and lasts six months and continues for three months after Koch’s bacillus is not found in the sputum culture. The BCG vaccine is intended for the active immunization of all newborns and high-risk children in order to prevent severe clinical forms of tuberculosis, as well as for the active immunization of adults with a high risk of developing tuberculosis. The aim of the research work is the comparison and interpretation of statistically processed data on the success of vaccination against TB on the territory of the Pomoravlje District for the period from 2008-2012. A descriptive study was applied in this research paper. The data were calculated in the SPSS statistics 20 software package. Results and discussion. Taking into account the total number of live births (1818) in relation to the number of vaccinated (1775) on the territory of the Pomoravlje District for the calendar year 2008, it is concluded that vaccination was successfully carried out for the specified year on the territory of one district because it amounted to 97.64% (it is greater than 95%). The percentage at the level of the entire district in 2009 is 97.34%, which indicates that immunization with the BCG vaccine was successfully implemented. Conclusion. Based on the statistically processed results, a high level of coverage and high success rate of the implemented vaccination for the five-year period from 2008-2012 was observed for the territory of the Pomoravlje District. It is very important to emphasize the essential measures that should be taken in every country of the world with the aim of developing and implementing national programs for the prevention, control and treatment of this disease.

1. E. Vynnycky, P. E. Fine, “Lifetime risks, incubation period, and serial interval of tuberculosis,” Am. J. Epidemiol.,vol.152, no. 3, pp. 247 – 263, Aug. 2000.
   DOI: 10.1093/aje/152.3.247
   PMid: 10933272
2. S. M. Blower, T. Chou, “Modeling the emergence of the “hot zones”: tuberculosis and the amplification dynamics of drug resistance,” Nat. Med. , vol. 10, no. 10, pp. 1111 – 1116, Oct. 2004.
   DOI: 10.1038/nm1102
   PMid: 15378053
3. D. Watrelot-Virieux, E. Drevon-Gaillot, Y. Toussaint, P. Belli, “Comparison of three diagnostic detection methods for tuberculosis in French cattle,” J. Vet. Med. B, vol. 53, no. 7, pp. 321 – 325, Sep. 2006.
   DOI: 10.1111/j.1439-0450.2006.00957.x
   PMid: 16930276
4. J. Kamerbeek et al., “Simultaneous detection and strain differentiation of Mycobacterium tuberculosis for diagnosis and epidemiology,” J. Clin. Microbiol. , vol. 35, no. 4, pp. 907 – 914, Apr. 1997.
   DOI: 10.1128/jcm.35.4.907-914.1997
   PMid: 9157152
   PMCid: PMC229700
5. C. Dye, Z. Fengzeng, S. Scheele, B. G. Williams, “Evaluating the impact of tuberculosis control: number of deaths prevented by short-course chemotherapy in China,” Int. J. Epidemiol., vol. 29, no. 3, pp. 558 – 564, Jun. 2000.
   DOI: 10.1093/intjepid/29.3.558
   PMid: 10869331
6. R. H. Wichelhausen, T. M. D. Brown, “Tuberculous peritonitis treated with streptomycin,” Am. J. Med., vol. 8, no. 4, pp. 421 – 444, Apr. 1950.
   DOI: 10.1016/0002-9343(49)90225-9
   PMid: 18115173
7. G. B. Migliori et al., “Frequency of recurrence among MDR-TB cases “successfully” treated with standardized short-course chemotherapy,” Int. J. Tuberc. Lung Dis. , vol. 6, no. 10, pp. 858 – 864, Oct. 2002.
   Retrieved from: https://books.google.rs/books?id=5wFM7Bu8FG0C&pg=PA647&lpg=PA647&dq=7.+G.+B.+Migliori+et+al.,+%22Frequency+of+recurrence+among+MDR-TB+cases+%E2%80%9Csuccessfully%E2%80%9D+treated+with+standardized+short
   Retrieved on: Jun. 10, 2023
8. D. Marinova, J. Gonzalo-Asensio, N. Aguilo, C. Martin, “Recent developments in tuberculosis vaccines,” Expert Rev. Vaccines, vol. 12, no. 12, pp. 1431 – 1448, Dec. 2013.
   DOI: 10.1586/14760584.2013.856765
   PMid: 24195481
9. R. L. Riley, “The contagiosity of tuberculosis,” Schweiz. Med. Wochenschr., vol. 113, no. 3, pp. 75 – 79, Jan. 1983.
   PMid: 6338584
10. R. Copin, M. Coscolla, E. Efstathiadis, S. Gagneux, J. D. Ernst, “Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG),” Vaccine, vol. 32, no. 45, pp. 5998 – 6004, Oct. 2014.
    DOI: 10.1016/j.vaccine.2014.07.113
    PMid: 25211768
    PMCid: PMC4539939
11. R. De la Rua-Domenech, “Human Mycobacterium bovis infection in the United Kingdom: Incidence, risks, control measures and review of the zoonotic aspects of bovine tuberculosis,” Tuberculosis,vol. 86, no. 2, pp. 77 – 109, Mar. 2006.
    DOI: 10.1016/j.tube.2005.05.002
    PMid: 16257579
12. E. Sumartojo, “When tuberculosis treatment fails. A social behavioral account of patient adherence,” Am. Rev. Respir. Dis., vol. 147, no. 5, pp. 1311 – 1320, May 1993.
    DOI: 10.1164/ajrccm/147.5.1311
    PMid: 8484650
13. T. L. Miller, S. J. N. McNabb, P. Hilsenrath, J. Pasipanodya, S. E. Weis, “Personal and societal health quality lost to tuberculosis,” PLoS ONE , vol. 4, no. 4, e5080, Apr. 2009.
    DOI: 10.1371/journal.pone.0005080
    PMid: 19352424
    PMCid: PMC2660416
14. C. Dye, P. Glaziou, K. Floyd, M. Raviglione, “Prospects for tuberculosis elimination,” Annu. Rev. Public Health, vol. 34, no. 34, pp. 271 – 286, Dec. 2013.
    DOI: 10.1146/annurev-publhealth-031912-114431
    PMid: 23244049
15. K. Lonnroth, E. Jaramillo, B. G. Williams, C. Dye, M. Raviglione, “Drivers of tuberculosis epidemics: The role of risk factors and social determinants,” Soc. Sci. Med., vol. 68, no. 12, pp. 2240 – 2246, Jun. 2009.
    DOI: 10.1016/j.socscimed.2009.03.041
    PMid: 19394122
16. C. Dye et al., “Measuring tuberculosis burden, trends, and the impact of control programmes,” Lancet Infect. Dis., vol. 8, no. 4, pp. 233 – 243, Apr. 2008.
    DOI: 10.1016/S1473-3099(07)70291-8
    PMid: 18201929
17. G. G. Guerrero, A. S. Debrie, C. Locht, “Boosting with mycobacterial heparin-binding haemagglutinin enhances protection of Mycobacterium bovis BCG-vaccinated newborn mice against M. tuberculosis,” Vaccine, vol. 28, no. 27, pp. 4340 – 4347, Jun. 2010.
    DOI: 10.1016/j.vaccine.2010.04.062
    PMid: 20447476
18. P. Beverley, “TB vaccine failure was predictable,” Nature, vol. 503, no. 7477, 469, Nov. 2013.
    DOI: 10.1038/503469e
    PMid: 24284721
19. S. J. Moore, M. Good, “The tuberculosis eradication programme in Ireland: a review of scientific and policy advances since 1988,” Vet. Microbiol ., vol. 112, no. 2-4, pp. 239 – 251, Dec. 2006.
    DOI: 10.1016/j.vetmic.2005.11.022
    PMid: 16337345